Emflaza
Marathon’s major misstep shows that drug pricing debate is here to stay
February 14, 2017Manufacturing and Production, Sales and Marketing Duchenne Muscular Dystrophy, Emflaza, marathon
Marathon Pharmaceuticals’ approval, last week, by the FDA for its treatment for Duchenne muscular dystrophy would usually have been cause …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
